Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2505 - Efficacy and safety of the combination of bevacizumab (BEV) and temsirolimus (TEM) in patients with metastatic renal cancer (mRCC) after first-line anti-VEGF treatment: A Hellenic Cooperative Oncology group (HeCOG) phase II trial


09 Oct 2016


Poster display


Konstantinos Koutsoukos


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


K. Koutsoukos1, F. Zagouri1, K. Tzannis1, V. Karavasilis2, E. Samantas2, G. Aravantinos2, A. Koutras2, I. Gkerzelis2, E. Chamylos2, E. Kostouros1, M. Lykka1, G. Tsironis1, I. Dimitriadis1, M. Liontos1, G. Fountzilas2, M. Dimopoulos1, A. Bamias1

Author affiliations

  • 1 Oncology Unit, Department Of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 115 28 - Athens/GR
  • 2 Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR


Abstract 2505


Anti vascular endothelial growth factor (aVEGF) agents represent the standard 1st-line therapy for mRCC. Monotherapy with agents blocking VEGF, mTOR or PD1/PD-L1 interaction are approved therapies. Since post progression blockade of VEGF may be of value, we studied the combination of BEV+TEM in mRCC patients relapsing after 1st-line treatment.


A prospective, phase II, multicenter, trial evaluating the combination of BEV(10mg/kg, every 2 weeks) withTEM(25 mg weekly), until progression of the disease or unacceptable toxicity, was conducted in patients with mRCC who failed first-line aVEGF treatment. No previous therapy for relapsed disease was allowed. % of 6-month progression-free survival (PFS) was the primary end point.


39 patients were enrolled and 37 of them were evaluable for response. 1st-line therapy included: sunitinib (16), bevacizumab/interferon (12), pazopanib (10), sorafenib (1). The median age was 67 (40-80) years. Clear cell histology was present in 97% of patients, while 69% had PS 0. 51% of patients were progression-free at 6 months (95% CIs: 34-66) and 20% (95% CIs: 9-34) at 12 months. The median time to progression was 6.8 months (95%CI 5.5-9.2) and the overall survival 18.2 months (95%CI 12.9-27.2). Best responses were: complete-1 (2.7%), partial-9(24.3%), stable disease-20 (54.1%), progression-7(18.9%). Worst toxicities were of grade: 1 in 1 case (3%), 2 in 20 (51%), 3 in 15 (38%), 4 in 2 (5%), 5 in 1 (3%). The most common adverse evets (AEs) were metabolic (44%), gastrointestinal (11%) and myelotoxicity (9%). The most common grade 3 and 4 AEs were infection (10%), hypertension (5%), hypertriglyceridemia (5%) and mucositis (5%).Toxicity was the most frequent cause of treatment discontinuation (33%).


The combination of BEV and TEMis active in mRCC patients relapsing after a VEGF 1st-line treatment. Our study confirms recent encouraging data of another anti-VEGF/anti-mTOR combination in this population. Nevertheless, toxicity was considerable leading to the discontinuation of therapy in 1/3 of patients.

Clinical trial identification


EudraCT: 2010-020664-38

Legal entity responsible for the study

Hellenic Cooperative Oncology Group




K. Koutsoukos: Honoraria from Novartis. F. Zagouri: Honoraria from Novartis, Roche. E. Kostouros: Honoraria Janssen. M. Liontos: Janssen Honoraria. M. Dimopoulos: Honoraria from Celgene, Janssen, Takeda and Amgen. A. Bamias: Pfizer, Roche, Novartis, Bayer (Honoraria). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings